Search Results
Your search for ,WHo matches 20839 pages
Showing 6701 - 6750Machine Learning Algorithm Is Successful in Predicting Malignancy in Patients With Multiple Pulmonary Nodules
Although guidelines exist for the use of several clinical prediction models based on logistic regression to help estimate the risk of lung cancer before treatment decision-making, they almost all focus on solitary pulmonary nodules, and have not shown accuracy in predicting malignancy in multiple...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
FDA Issues Emergency Use Authorization for Third COVID-19 Vaccine
On February 27, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the third vaccine for the prevention of COVID-19. The EUA allows the Janssen COVID-19 Vaccine to be distributed in the United States for use in individuals 18 years of age and older. The FDA...
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (Pepaxto) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is...
Enfortumab Vedotin-ejfv in Previously Treated Advanced Urothelial Carcinoma
As reported in The New England Journal of Medicine by Powles et al, a prespecified interim analysis of the phase III EV-301 trial has shown improved overall survival with enfortumab vedotin-ejfv vs investigator choice of chemotherapy in patients with previously treated advanced urothelial...
EMPOWER-Lung 1: First-Line Cemiplimab-rwlc vs Platinum-Doublet Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 50%
As reported in The Lancet by Sezer et al, the phase III EMPOWER-Lung 1 trial has shown improved overall and progression-free survival with cemiplimab-rwlc vs platinum doublet chemotherapy among patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression on ≥ 50% of tumor cells...
Updates From Selected Clinical Trials in Breast Cancer
Each year, following the San Antonio Breast Cancer Symposium (SABCS), The ASCO Post asks Jame Abraham, MD, FACP, to offer his picks of the most important and most clinically relevant research presented at this meeting. The following are summaries of studies that caught Dr. Abraham’s attention from ...
The Impact of a Pandemic on Mentorship in Medicine
When advising the younger members of our medical community on career decisions, I always list “access to the best mentorship” as the most important priority. By the time we hit residency, we have all proven ourselves able to extract from a book or a journal the facts essential to the practice of...
Expert Point of View: Michael Overman, MD
At the 2021 Gastrointestinal Cancers Symposium, the KEYNOTE-177 investigators updated their previously reported findings by showing further data relating to subsequent lines of therapy after disease progression. Their conclusion was that patients who received pembrolizumab initially still achieved...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial in microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to immunotherapy for...
Endoscopic Nasopharyngectomy vs IMRT for Previously Treated, Resectable, Locally Recurrent Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that endoscopic nasopharyngectomy was associated with improved overall survival vs intensity-modulated radiotherapy (IMRT) in patients with resectable locally recurrent nasopharyngeal carcinoma who had received prior...
LuPSMA Leads to Improved PSA Response, Fewer Severe Adverse Events Than Cabazitaxel in Patients With Metastatic Prostate Cancer
In the Australian phase II trial TheraP reported in The Lancet, Michael S. Hofman, FRACP, MBBS, and colleagues found that Lutetium-177–labeled PSMA-617 (LuPSMA) treatment was associated with a higher prostate-specific antigen (PSA) response rate and fewer severe adverse events vs cabazitaxel in...
New Report Reviews Methods for Reducing Waste, Improving Efficiency With Expensive Injectable Medications
Every year, significant amounts of drugs left over and unused from single-dose vials are discarded, but because of the way drugs are priced and paid for in the United States, the cost of the discarded amount cannot be recouped, according to a new congressionally mandated report from the National...
Biden Administration, New Congress Review Recent Rules Affecting Cancer Care Delivery
In the days and weeks leading up to President Biden’s inauguration, the Department of Health and Human Services (HHS)—under the prior administration—issued a number of rules and regulations that affect cancer care delivery. Many of those rules and regulations are now subject to review by the new...
New Framework to Address Cancer Care Disparities in Medically Underserved Populations
A new article published in JCO Oncology Practice puts forth a framework to guide researchers, health-care leaders, advocates, community- and patient-focused service organizations, and policy leaders in their work to address and promote health equity in cancer care access and treatment outcomes.1...
In Case You Missed It: Brief Highlights From ASH 2020
In case you missed these while attending the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, below is a sampler of highlights that were not included in our first round of meeting coverage. Many of these reports are on early-phase clinical trials of agents that may raise...
Expert Point of View: Lucia Masarova, MD
Lucia Masarova, MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, said the updated long-term data for momelotinib show “durable efficacy and exciting outcomes” in patients with myelofibrosis, regardless of prior exposure to...
SIMPLIFY Trials: JAK Inhibitor Yields Long-Term Survival Benefit and Transfusion Independence in Myelofibrosis
Treatment with the novel JAK inhibitor momelotinib led to long-term overall survival and sustained transfusion independence in patients with intermediate- or high-risk myelofibrosis, according to updates from the SIMPLIFY-1 and SIMPLIFY-2 trials presented at the 2020 American Society of Hematology...
I Let Science, Not Emotion, Dictate My Treatment
I had my first experience with cancer when I was just 3 or 4 years old and complained to my mother that my “tummy hurt.” I was diagnosed with Wilms tumor, the same cancer my 18-month-old brother died of before I was born. I remember being in the hospital for weeks at a time and being known by...
When to Start a Conversation With Patients About Subsequent Primary Cancers
Among patients who survive a primary cancer, concern about recurrence, especially metastatic disease, is extremely common; however, information about future risk for subsequent primary cancers is seldom communicated to these patients, leading to missed opportunities to prevent or detect subsequent...
Ongoing Surveillance and Efforts to Reduce Smoking and Obesity Needed to Lower Cancer Survivors’ Risks of New Cancers
The risk of developing or dying of a new primary cancer, particularly those cancers associated with smoking and obesity, was greater among survivors of adult-onset cancers than the expected risk in the general population, according to an analysis of data from more than 1.5 million cancer...
KEYNOTE-598: No Improvement With Addition of Ipilimumab to Pembrolizumab in NSCLC
In the phase III KEYNOTE-598 study, the addition of ipilimumab to pembrolizumab increased toxicity without boosting efficacy as first-line therapy for metastatic non–small cell lung cancer (NSCLC) in patients with high expression of PD-L1. The findings were presented at the International...
Professor Gordon McVie, International Cancer Researcher and Patient Advocate, Dies at 76
An imposing painting of sailing ships graced the wall behind the desk in the office of Professor Gordon McVie, BSc (Hons), MBChB, MD, FRCP, FRCPEd, FRCPS (Glas), FMedSci, DSc. It was a gift from one of his patients with cancer, a long-term survivor who said the painting reminded her of him, walking ...
John Bartlett, MD, Pioneer in Infectious Diseases Research and Treatment, Dies at 83
John Bartlett, MD, a visionary physician-scientist and pioneer in HIV/AIDS study and treatment who built the infectious diseases division at The Johns Hopkins, died on January 19, 2021, in New York. He was 83 years old. “Over his long and illustrious career, John Bartlett epitomized the best of...
Gert Brieger, MD, MPH, PhD, Historian of Medicine and Public Health, Dies at 89
Gert Brieger, MD, MPH, PhD, former Director of the Johns Hopkins University School of Medicine Institute of the History of Medicine, died on January 13, 2021, due to heart failure. He was 89. Dr. Brieger is credited with transforming the department from a research center with occasional students to ...
Joseph V. Simone, MD, Visionary Pediatric Oncologist and ‘Quintessential Mentor,’ Dies at 85
When Joseph V. Simone, MD, was 6 years old, he had his first experience with the death of a child. His 9-month-old brother became sick with the croup and was taken to the nearby children’s hospital, where he died a few days later, leaving Dr. Simone and his family devastated. Caring for sick...
Conversations With the Pioneers of Oncology: Emil J Freireich, MD, FASCO
To hear an interview with Dr. Freireich by Daniel F. Hayes, MD, FASCO, of the University of Michigan Rogel Cancer Center and Past President of ASCO, visit the Journal of Clinical Oncology’s podcast, Cancer Stories, wherever you get your podcasts. In this episode, the Cancer Stories podcast reflects ...
The CARG-BC Score: Novel Tool for Predicting Chemotherapy Toxicity in Early-Stage Breast Cancer
As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, of the University of Rochester Medical Center & Wilmot Cancer Institute, and Mina S. Sedrak, MD, MS, of the City of Hope National Medical Center, along with colleagues, have developed a novel risk tool—the Cancer and Aging...
COVID-19 and Cancer: A Toxic Combination
COVID-19 has caused 475,000 deaths in America, disproportionately among communities of color, poverty, immigrants, and older age. It has exposed a variety of inequities within our health-care system. However, the patients at greatest risk of death from COVID-19 are those with cancer. While 1.8% of...
Genome-Edited Donor-Derived Anti-CD19 CAR T-Cell Therapy Is Active in B-Cell Acute Lymphoblastic Leukemia
Pooled results of two phase I studies, reported in The Lancet by Reuben Benjamin, MBBS, of the Department of Haematological Medicine, King’s College Hospital, London, and colleagues, indicate that the genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product...
Novel Approaches in Chronic Lymphocytic Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic approaches in chronic lymphocytic leukemia (CLL). For full...
FGFR2 Inhibitor Infigratinib Active in Chemotherapy-Refractory Cholangiocarcinoma
The novel targeted agent infigratinib (BGJ398) showed clinically meaningful activity against chemotherapy-refractory cholangiocarcinoma in patients with fibroblast growth factor receptor (FGFR2) fusions and rearrangements. The confirmed overall response rate was 23% (34% confirmed/unconfirmed), the ...
B-Cell and T-Cell Non-Hodgkin Lymphomas
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on the assessment and treatment of patients with B-cell and T-cell non-Hodgkin...
Expert Point of View: Pasi A. Jänne, MD, PhD, and Charu Aggarwal, MD, MPH
The invited discussant of CodeBreak 100 was Pasi A. Jänne, MD, PhD, Professor of Medicine at Harvard Medical School and a thoracic oncologist at Dana-Farber Cancer Institute, Boston.1Charu Aggarwal, MD, MPH, Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of...
Phase II CodeBreak 100 Validates Benefit of KRAS Inhibitor Sotorasib in Advanced Lung Cancer
The registrational phase II CodeBreak 100 trial has validated the power of KRAS inhibition with sotorasib (AMG 510) in advanced non–small cell lung cancer (NSCLC).1 In a follow-up to the groundbreaking findings of the phase I trial, the phase II cohort has now shown a durable response rate of...
United States Surpasses 500,000 Deaths Due to COVID-19
On February 22, President Joseph R. Biden issued remarks to proclaim that over 500,000 Americans have now died from COVID-19 infection. He and Vice President Kamala Harris held a moment of silence and ordered flags be lowered to half-mast at federal buildings for the next 5 days to honor those who...
Responses to Anti–PD-1/PD-L1 Immunotherapy in Patients With MSS Solid Tumors and High Tumor Mutational Burden
In a single-institution study reported in JAMA Oncology, Valero et al found that response rates to anti–PD-1 or anti–PD-L1 treatments in patients with microsatellite-stable (MSS) solid tumors were generally higher among those with high tumor mutational burden (TMB) defined as ≥ 10...
Bone Metastatic Burden and Survival Outcomes With Prostate Radiotherapy for Newly Diagnosed Metastatic Disease
In an analysis from the STAMPEDE trial reported in JAMA Oncology, Ali et al found that a lower number of bone metastases was associated with improved overall and failure-free survival in patients receiving prostate radiotherapy for newly diagnosed M1 metastatic prostate cancer. Study Details The...
Expert Point of View: Meredith Regan, ScD, and Sara Hurvitz, MD
In the San Antonio meeting’s closing session, “View From the Trenches: What Will You Do Monday Morning?” Meredith Regan, ScD, and Sara Hurvitz, MD, offered their thoughts on the use of RSClin in the clinic, as described at the San Antonio Breast Cancer Symposium by Joseph Sparano, MD.1 Dr. Regan...
Prognostic Tool RSClin Introduced for Early Breast Cancer
Data from the TAILORx study and several National Surgical Adjuvant Breast and Bowel Project (NSABP) trials have been used to develop a new prognostic tool, RSClin, which aims to individualize the estimate of recurrence risk in early breast cancer and to more accurately predict the risk-reduction...
Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib
Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of...
Bevacizumab Beyond Disease Progression Plus Carboplatin-Based Doublet in Platinum-Sensitive Ovarian Cancer
In the phase III MITO16b/MANGO–OV2/ENGOT–ov17 trial, investigators found that treatment with a carboplatin-based doublet plus bevacizumab beyond disease progression significantly improved progression-free survival vs a carboplatin-based doublet alone in women with platinum-sensitive ovarian cancer...
Can Weight Loss During Treatment and Follow-up Affect Breast Cancer Outcomes?
Research published by Martel et al in JNCCN—Journal of the National Comprehensive Cancer Network examined body mass index (BMI) data for patients with HER2-positive early breast cancer—and found a 5% weight loss in patients over 2 years was associated with worse outcomes. Weight gain over the same...
MRI-Targeted Biopsy vs Systematic Transrectal Ultrasonography Biopsy for Detection of Disease in Men at Risk for Prostate Cancer
In a Canadian phase III trial reported in JAMA Oncology, Klotz et al found that multiparametric magnetic resonance imaging (MRI) with targeted biopsy was noninferior to systematic 12-core transrectal ultrasonography biopsy in detecting International Society of Urological Pathology grade group 2...
Felix Y. Feng, MD, on Prostate Cancer: Choosing Patients Who May Benefit From Apalutamide
Felix Y. Feng, MD, of the University of California, San Francisco, discusses study findings showing that molecular determinants may help clinicians select patients with nonmetastatic castration-resistant prostate cancer who may derive the most benefit from apalutamide and other androgen-signaling...
FDA Approves Cemiplimab-rwlc for Patients With NSCLC and High PD-L1 Expression
On February 22, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] > 50%) as determined by an FDA-approved...
Telephone-Supported Depression Self-Care Intervention for Cancer Survivors
In a Canadian study reported in the Journal of Clinical Oncology, McCusker et al found that a telephone-supported depression self-care intervention called CanDirect was effective in managing mild-to-moderate depression symptoms in cancer survivors. Study Details The study involved 245 patients who...
NEOSTAR: Neoadjuvant Nivolumab or Nivolumab/Ipilimumab in Operable NSCLC
The randomized phase II NEOSTAR trial, which examined single-agent and combined neoadjuvant immune checkpoint inhibitor therapy in patients with stage I to III non–small cell lung cancer (NSCLC), found combination therapy produced a significant clinical benefit (as assessed by major pathologic...
Addition of Second-Line Pegilodecakin to FOLFOX in Metastatic Pancreatic Cancer: SEQUOIA Trial
In the phase III SEQUOIA trial reported in the Journal of Clinical Oncology, J. Randolph Hecht, MD, and colleagues found that the addition of pegilodecakin—a pegylated recombinant human interleukin (IL)-10—to FOLFOX (leucovorin, fluorouracil [5-FU], and oxaliplatin) did not improve overall survival ...
